Literature DB >> 12777656

Treatment of severe acute respiratory syndrome with convalescent plasma.

V W S Wong1, D Dai, A K L Wu, J J Y Sung.   

Abstract

In March 2003, an outbreak of severe acute respiratory syndrome started in Hong Kong. A 57-year-old woman had a typical presentation, including fever, non-productive cough, malaise, lymphopenia, and raised liver aminotransferases. The clinical course and successful treatment with convalescent plasma, ribavirin, and corticosteroids are discussed.

Entities:  

Mesh：

Year:  2003        PMID： 12777656

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN： 1024-2708            Impact factor:   2.227


  62 in total

Review 1.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

2.  B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.

Authors:  Xiaofen Zhong; Huanghao Yang; Zu-Feng Guo; Wan-Yee Fion Sin; Wei Chen; Junjie Xu; Ling Fu; Jie Wu; Chun-Kit Gannon Mak; Chak-Sum Samuel Cheng; Yanzhen Yang; Shuyong Cao; Tin-Yau Wong; Sik-To Lai; Yong Xie; Zhihong Guo
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.

Authors:  Xian-Chun Tang; Wayne A Marasco
Journal:  Immunotherapy       Date:  2015-06-22       Impact factor: 4.196

4.  Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.

Authors:  Jianhua Sui; Wenhui Li; Anjeanette Roberts; Leslie J Matthews; Akikazu Murakami; Leatrice Vogel; Swee Kee Wong; Kanta Subbarao; Michael Farzan; Wayne A Marasco
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Suggested management of immunocompromized kidney patients suffering from SARS.

Authors:  Man-Chun Chiu
Journal:  Pediatr Nephrol       Date:  2003-10-24       Impact factor: 3.714

Review 6.  Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.

Authors:  Vincent C C Cheng; Susanna K P Lau; Patrick C Y Woo; Kwok Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

Review 7.  Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Authors:  Evan M Bloch; Shmuel Shoham; Arturo Casadevall; Bruce S Sachais; Beth Shaz; Jeffrey L Winters; Camille van Buskirk; Brenda J Grossman; Michael Joyner; Jeffrey P Henderson; Andrew Pekosz; Bryan Lau; Amy Wesolowski; Louis Katz; Hua Shan; Paul G Auwaerter; David Thomas; David J Sullivan; Nigel Paneth; Eric Gehrie; Steven Spitalnik; Eldad A Hod; Lewis Pollack; Wayne T Nicholson; Liise-Anne Pirofski; Jeffrey A Bailey; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 8.  A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.

Authors:  Nishat Fatima; Vichitra Kaushik; Amjad Ayoub
Journal:  Iran J Med Sci       Date:  2021-05

9.  Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.

Authors:  Susan Yonemura; Lindsay Hartson; Taru S Dutt; Marcela Henao-Tamayo; Raymond Goodrich; Susanne Marschner
Journal:  Vox Sang       Date:  2021-04-09       Impact factor: 2.996

Review 10.  Plasma therapy: a passive resistance against the deadliest.

Authors:  Anita Hansda; Debarati Biswas; Aishwarya Bhatta; Nishant Chakravorty; Gayatri Mukherjee
Journal:  Hum Vaccin Immunother       Date:  2021-12-09       Impact factor: 4.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.